CA-ANALOGIX-SEMI
20.5.2019 15:02:12 CEST | Business Wire | Press release
Analogix Semiconductor, Inc. today announced the availability of its VirtualLink™ Reference Design which enables VirtualLink directly on the motherboard of high-performance gaming notebooks, allowing them to support virtual reality (VR) over the USB-C™ connector. External accessories can also leverage the reference design to interface legacy graphics processing units (GPUs) to future VirtualLink-enabled VR head-mounted displays.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005132/en/
Introduced by a consortium led by NVIDIA, Oculus, Valve, AMD, and Microsoft, the VirtualLink Alternate Mode of USB Type-C™ was designed to deliver the power, display, and data required to power VR headsets through a single USB Type-C connector, eliminating the need for multiple cables. It expands on the USB Type-C connector’s capabilities to deliver high-definition video at high frame rates, high-speed 10Gpbs USB-C data for camera and sensor communication back to the VR source, and up to 27W power delivery to the VR headset.
The Analogix VirtualLink reference design system consists of:
- Input: 4-lane DisplayPort 1.4 and 1-lane USB 3.2 Gen2;
- Output: USB-C with power delivery (PD) and support for DisplayPort™ Alt Mode and VirtualLink Alternate Mode;
- ANX7440 – USB-C Mux with active re-timer solution, fully compliant to USB 3.2 and DisplayPort 1.4 specifications, with insertion loss compensation to recover up to 23dB channel loss for USB 3.2 Gen 2 10 Gbps, and up to 27dB for DisplayPort 8.1G;
- ANX7428 – fast center switch capable of switching between USB 2.0 and USB 3.2 signals with excellent crosstalk performance at 10G for DisplayPort Alt Mode and VirtualLink applications;
- ANX7430 – USB 3.2 Gen2 active re-timer for dedicated high-speed USB data path;
- ANX7411 – USB-C port controller with USB PD 3.0.
“Connecting and powering a tethered VR headset environment today involves multiple cables; the goal is to leverage a single connector solution that simplifies set-up and maintains high-performance,” said Michael Ching, vice president of marketing for Analogix. “The Analogix VirtualLink RD brings VirtualLink and VR support to gaming laptops of any size with a single USB-C port.”
All system components are in full production and the reference design will be available for purchase from Analogix by July 2019.
Product demonstrations will be taking place during Computex Taipei May 28 – Jun 1, 2019 at Analogix’s exhibitor suite # 1105 & 1106 at The Grand Hyatt Taipei.
About Analogix Semiconductor
Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones, notebooks, and AR/VR head mounted displays, to large, high-definition TVs and high-end graphics cards. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort under its SlimPort brand, including high-speed signal conditioners, and an industry leader in mobile display controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector.
For more information visit www.analogix.com and www.slimport.com , follow us on Twitter @Analogix and @SlimPortConnect , or connect with us on LinkedIn .
Analogix and SlimPort are trademarks or registered trademarks of Analogix Semiconductor, Inc. All other trademarks and trade names are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005132/en/
Contact:
Analogix Media Contact Gratia Stefan Tel: 408-988-8848 marcom@analogix.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom